ACCENDRA HEALTH INC/VA/ financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ACCENDRA HEALTH INC/VA/ files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	9,723	9,318	9,418	9,211	8,480	9,785	9,955	2,553	2,680	2,762
Cost of revenue	8,536	8,146	8,348	8,082	7,199	8,272	8,129	1,336	1,400	1,473
Gross profit	1,187	1,172	1,071	1,128	1,281	1,513	1,826	2,125	2,219	1,289
Research and development						12.1	12	13	13
Selling, general and administrative	970	1,017	953	1,023	1,041	1,077	1,555	1,002	1,082	1,068
Operating income	200	89.3	-352	73.2	204	368	143	133	-218	27.5
Interest expense	27.1	31.8	71	98.1	83.4	48.1	129	117	108	107
Other non-operating income			-3.77	-2.93	0.41	-3.2	-3.13	-1.2	-4.59	-3.94
Pre-tax income	173	57.5	-427	-28.7	110	277	10.9	15.3	-330	-102
Income tax	63.8	-15.3	-32.4	-6.14	21.8	55.2	-11.5	6.36	20.9	0.73
Income from continuing operations			-395	-22.6	88.1	222	22.4	8.91	-351	-103
Net income	109	72.8	-437	-62.4	29.9	222	22.4	-41.3	-363	-1,101
EBITDA	255	149	-250	190	297	459	372	344	-36.4	242
EPS, basic	1.76	1.20	-7.28	-1.03	0.47	3.05	0.30	-0.54	-4.73	-14.31
EPS, diluted	1.76	1.20	-7.28	-1.03	0.47	2.94	0.29	-0.53	-4.73	-14.31
Shares, basic (weighted)	61.1	60	60	60.6	63.4	72.7	74.5	75.8	76.7	76.9
Shares, diluted (weighted)	61.1	60	60	60.6	63.5	75.5	76.2	77.4	76.7	76.9
Dividend per share	1.02	1.03	0.86	0.01	0.01	0.01

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	185	105	66.3	67	83.1	55.7	69.5	243	27.6	282
Inventory	916	990	1,274	1,146	1,234	1,496	1,334	1,111	67.6	74.4
Other current assets	254	328	122	79.4	118	88.6	129	151	82.2	95.5
Total current assets	1,962	2,182	2,539	2,407	2,136	2,322	2,295	2,103	2,021	548
Property, plant and equipment	192	206	324	315	316	317	578	544	249	256
Lease right-of-use assets			0	142	145	194	281	297	127	109
Goodwill	415	687	414	393	394	390	1,637	1,639	1,228	1,228
Intangible assets	82.5	184	314	285	243	210	445	362	210	136
Other non-current assets	66.5	89.6	84.5	100	102	104	150	149	89.5	174
Total assets	2,718	3,376	3,774	3,643	3,336	3,537	5,386	5,093	4,656	2,452
Accounts payable	751	948	1,065	808	1,000	1,002	1,147	1,172	360	364
Accrued liabilities	45.1	13	38.4	53.6	109	116	93.3	116	73.7	69.4
Short-term debt	4.8	16.6	28.7	51.2	39.9		17.9	207	42.9	250
Total current liabilities	1,035	1,310	1,472	1,416	1,346	1,344	1,566	1,892	1,852	947
Long-term debt	565	901	1,648	1,508	986	948	2,483	1,891	1,798	1,800
Lease liabilities			0	117	120	162	215	222	89.5	70.3
Other non-current liabilities	68.1	76.1	77.7	98.7	121	109	115	123	72.6	95.5
Total liabilities	1,758	2,361	3,255	3,181	2,624	2,598	4,441	4,169	4,070	2,913
Total debt	569	917	1,677	1,560	1,026	948	17.9	207	42.9	250
Paid-in capital	220	227	239	251	437	441	419	434	454	467
Retained earnings	686	691	201	138	167	388	410	369	27.2	-1,080
Other comprehensive income	-67.5	-25.1	-45.6	-52.7	-38.5	-40.6	-35.9	-31.8	-49.3	-0.89
Shareholders' equity	960	1,015	518	462	712	939	967	945	586	-461
Total equity	960	1,015	518	462	712	939	967	945	586	-461
Total liabilities and equity	2,718	3,376	3,774	3,643	3,336	3,537	5,386	5,093	4,656	2,452
Shares outstanding	61	61.5	61.5	62.8	73.5	75.4	76.3	76.5	77.2	76.4

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	109	72.8	-437	-62.4	29.9	222	22.4	-41.3	-363	-1,101
Depreciation and amortization	55.4	59.4	102	117	93.3	90.6	229	210	181	215
Stock-based compensation	12	11.9	16.4	15.8	20	25	21	14.4	16.6	12.9
Deferred income tax	4.22	-50	-35.1	-17.4	15.6	-29.7	-26.4	-6	-8.04	-17.9
Change in inventory	22.6	-57	-65.5	128	-85.2	-263	167	-5.35	-4.59	-6.85
Cash from operations	188	56.8	116	166	339	124	325	741	161	-102
Capital expenditures	-20.3	-34.6	-44.9	-42.4	-50.4	-41	-158	-172	-170	-191
Acquisitions	0	-367	-752	0	0	0	-1,685	0		-18.1
Cash from investing	-24.7	-417	-816	-51.9	80.1	-53.6	-1,804	-137	-117	144
Debt issued	0	250	696	0	155	575	1,691	0	0
Debt repaid	0	-3.13	-16.3	-85.6	-617	-553	-4.5	-321	-244
Stock issued	0			0	190	0	0
Share buybacks	-71	-5	0							-10.2
Dividends paid	-63.4	-63.2	-48.2	-5.23	-0.65	-0.73	0	0
Cash from financing	-143	273	701	-130	-379	-129	1,497	-417	-268	188
Exchange rate effect	4.22	6.1	-1.99	-2.67	9.91	-3.54	-3.49	0.61	-0.9	1.9
Net change in cash	24.5	-81	-1.16	-18.7	49.8	-62.5	14.2	187	-224	233
Free cash flow	167	22.2	70.7	124	289	83.2	167	568	-8.79	-293
Interest paid	27.9	30.6	68.6	95.4	90	38.7	107	153	142	135
Income taxes paid	74.1	41.8	19.2	-6.2	-17.5	99.4	34	-6.28	5.55	12.5

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.71 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	44.8%	Gross profit / revenue.
Operating margin	1.1%	Operating income / revenue.
EBITDA margin	10.8%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	-4.4%	Pre-tax income / revenue.
Net margin	-11.4%	Net income / revenue.
Return on assets (ROA)	-14.3%	Net income / average total assets.
SG&A / revenue	39.1%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	0.4%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	6.7%	Capital expenditures / revenue.
D&A / revenue	9.7%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	3.1%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-34.8%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	-20.1%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-41.9%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	-11.0%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	0.1%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income CAGR, 3y	-42.3%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	-33.0%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA CAGR, 3y	-13.3%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	-4.0%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	-163.0%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y	-178.6%	Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y	-47.3%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-23.1%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-6.0%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	0.2%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	0.3%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	3.9%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	0.41x	Current assets / current liabilities.
Quick ratio	0.01x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.01x	(Cash + short-term investments) / current liabilities.
Debt / assets	0.0%	Total debt / total assets.
Liabilities / assets	126.1%	Total liabilities / total assets.
Net debt	-$7.7M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	-0.03x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	0.24x	Operating income / interest expense.
Working capital	-$394.8M	Current assets - current liabilities.
Goodwill and intangibles / assets	62.0%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$1.86B	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	1.26x	Revenue / average total assets.
Fixed asset turnover	12.7x	Revenue / average property, plant and equipment.
Inventory turnover	19.9x	Cost of revenue / average inventory.
Days inventory	18 days	365 x average inventory / cost of revenue.
Days payables	88 days	365 x average accounts payable / cost of revenue.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$3.94	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$34.52	Revenue / diluted weighted shares.
Book value per share	-$7.16	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$24.15	Tangible book value / shares outstanding.
Cash per share	$0.10	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$54.4M	Share price x shares outstanding.
Enterprise value	$46.8M	Market cap + total debt - cash - short-term investments.
P/S	0.02x	Market cap / revenue.
EV/Sales	0.02x	Enterprise value / revenue.
EV/EBIT	1.59x	Enterprise value / operating income, when both are positive.
EV/EBITDA	0.16x	Enterprise value / EBITDA, when both are positive.
Earnings yield	-554.9%	Net income / market cap (the inverse of P/E).

What was ACCENDRA HEALTH INC/VA/'s revenue in fiscal 2025?

ACCENDRA HEALTH INC/VA/ reported revenue of $2.76B for fiscal 2025, 3.1% higher than the year before.

Was ACCENDRA HEALTH INC/VA/ profitable in fiscal 2025?

No. It reported a net loss of $1.10B.

How much free cash flow did ACCENDRA HEALTH INC/VA/ generate in fiscal 2025?

Cash from operations of $101.8M minus capital expenditures of $191.0M left free cash flow of -$292.7M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to ACCENDRA HEALTH INC/VA/